Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label single-arm study of PTT-621 in moderately to severely active ulcerative colitis
CTR20262689Phase 2Active
- Sponsor
- Pyrotech Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PTT-621 in autoimmune colitis, sponsored by Pyrotech Therapeutics. Started Jul 2026; status: active.
02
Drugs
PTT-621
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20262689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262689.